Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4310 [18F]AlF-NOTA-octreotide as tracer for somatostatin receptor PET/CT: Retrospective analysis of the clinical use in 288 neuroendocrine tumour patients

Introduction: [18F]AlF-NOTA-octreotide has emerged as a reliable tracer for somatostatin receptor (SSTR) PET/CT in patients with neuroendocrine neoplasms (NENs). Although effective and logistically advantageous, there remains limited data on its routine clinical application, particularly for specific NEN subtypes (e.g. NET G3).

Conference:

Presenting Author: Leupe H

Authors: Leupe H, Dekervel J, Cleeren F, Goffin K, Dooms C,

Keywords: [18F]AlF-NOTA-octreotide, routine clinical use, neuroendocrine tumour, somatostatin receptor, PET/CT imaging,

#4050 PET/CT imaging of the somatostatin receptor with [18F]AlF-NOTA-octreotide PET/CT: Analysis of impact on tumor staging and therapeutic management

Introduction: [18F]AlF-NOTA-octreotide ([18F]AlF-OC) is a promising alternative for [68Ga]Ga-DOTA-somatostatin analogues (SSAs) in PET imaging of the somatostatin receptor (SST).

Conference:

Presenting Author: Leupe H

Authors: Leupe H, Vandamme T, van den Broeck B, Lybaert W, Dekervel J,

Keywords: Neuroendocrine tumor, nuclear medicine, PET imaging, somatostatin receptor, [68Ga]Ga-DOTA-SSA, [18F]AlF-NOTA-octreotide,

#2947 Al18F-NOTA-Octreotide PET Imaging of the Somatostatin Receptor: First Comparison with 68Ga-DOTATATE in Neuroendocrine Tumor Patients

Introduction: Practical and economic challenges limit the widespread use of 68Ga-labeled somatostatin analog (SSA) PET, the current standard for somatostatin receptor imaging. A promising 18F-labeled SSA, Al18F-NOTA-octreotide (Al18F-OC), has recently been introduced.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K,

Keywords: neuroendocrine tumors, PET, Al18F-NOTA-octreotide, 68Ga-DOTATATE, somatostatin receptor imaging,

#517 Initial Experience of Biological Stability and Image Timing of Ga-68 DOTANOC in Somatostatin Receptor (sstr) Expressing Organ and Tumor

Introduction: Since Ga68 DOTATATE has a high affinity to only sstr2 but no affinity to sstr3 and sstr5, Ga68 DOTANOC has been suggested to be a better radioligand with higher affinity to sstr3 and sstr5 and high affinity to sstr2, as well.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Demirci E, Kabasakal L, Ocak M, Aygun A, Ozcan R,

Keywords: Octreotide PET,

#516 Evaluation of 68Ga-DOTA-TATE and 68Ga-DOTA-LAN PET/CT in Somatostatin Exopressing Organs and Tumors

Introduction: Octreotide derived radiolabelled peptides have been widely used for somatostatin receptor (sstr) imaging. Clinically used radiopeptides exclusively target sstr subtype 2. But radiolabeled Lanreotide has been claimed to bind sstr 2, 3 and 5.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Kabasakal L, Demirci E, Ocak M, Aygun A, Decristoforo C,

Keywords: Octreotide PET,